




Instance: composition-en-e635923c4f0c1291555b7edc27db8608
InstanceOf: CompositionUvEpi
Title: "Composition for zostavax Package Leaflet"
Description:  "Composition for zostavax Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/06/341/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpe635923c4f0c1291555b7edc27db8608)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - zostavax"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  
  </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol type="1">
<li>What ZOSTAVAX is and what it is used for</li>
<li>What you need to know before you receive ZOSTAVAX</li>
<li>How to use ZOSTAVAX</li>
<li>Possible side effects</li>
<li>How to store ZOSTAVAX</li>
<li>Contents of the pack and other information</li>
</ol>
 </div>"""   
          

* section[=].section[+]
  * title =  "1. What zostavax is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What zostavax is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>ZOSTAVAX is a vaccine used to prevent shingles (zoster) and
zoster-related post-herpetic neuralgia (PHN), the long-lasting nerve
pain that follows shingles. ZOSTAVAX is used to vaccinate individuals 50
years of age or older. ZOSTAVAX cannot be used to treat existing
shingles or the pain associated with existing shingles. Disease
information on shingles: What is shingles? Shingles is a painful,
blistering rash. It usually occurs in one part of the body and can last
for several weeks. It may lead to severe and long-lasting pain and
scarring. Less commonly, bacterial skin infections, weakness, muscle
paralysis, loss of hearing or vision can occur. Shingles is caused by
the same virus that causes chickenpox. After you have had chickenpox,
the virus that caused it stays in your body in nerve cells. Sometimes,
after many years, the virus becomes active again and causes shingles.
What is PHN? After the shingles blisters heal, pain can last for months
or years and may be severe. This long-lasting nerve pain is called
post-herpetic neuralgia or PHN.</p>
 </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take zostavax"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take zostavax"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not receive ZOSTAVAX</p>
<p>if you are allergic to any of the components of this vaccine
(including neomycin (which may be present as trace residue) or any of
the other ingredients listed in section 6)</p>
<p>if you have a blood disorder or any type of cancer that weakens your
immune system</p>
<p>if you have been told by your doctor that you have a weakened immune
system as a result of a disease, medicines, or other treatment</p>
<p>if you have active untreated tuberculosis</p>
<p>if you are pregnant (in addition, pregnancy should be avoided for 1
month after vaccination, see Pregnancy and breast-feeding). Warnings and
precautions If you have experienced any of the following, talk to your
doctor or pharmacist before receiving ZOSTAVAX:</p>
<p>if you have or have had any medical problems or any allergies</p>
<p>if you have a fever</p>
<p>if you have HIV infection Tell your doctor if you have ever had an
allergic reaction to any of the ingredients (including neomycin (which
may be present as trace residue) or any of the ingredients listed under
section 6) before you receive this vaccine. As with many vaccines,
ZOSTAVAX may not completely protect all persons who are vaccinated. If
you have a blood clotting disorder or low levels of platelets, the
vaccine should be given under the skin because bleeding may occur
following administration into the muscle. Other medicines and ZOSTAVAX
Tell your doctor or pharmacist if you are taking, have recently taken or
might take any other medicines or vaccines. ZOSTAVAX can be administered
at the same time as inactivated influenza vaccine. The two vaccines
should be given as separate injections at different body sites. For
information about the administration of ZOSTAVAX and pneumococcal
polysaccharide vaccine at the same time, talk to your doctor or health
care provider. Pregnancy and breast-feeding ZOSTAVAX should not be given
to pregnant women. Women of child-bearing potential should take the
necessary precautions to avoid pregnancy for 1 month following
vaccination. Inform your doctor if you are breast-feeding or intending
to breast-feed. Your doctor will decide if ZOSTAVAX should be given. If
you are pregnant or breast-feeding, think you may be pregnant, or are
planning to have a baby, ask your doctor or pharmacist for advice before
receiving this vaccine. Driving and using machines There is no
information to suggest that ZOSTAVAX affects the ability to drive or use
machines. ZOSTAVAX contains sodium This medicine contains less than 1
mmol sodium (23 milligrams) per dose, that is to say essentially
sodium-free'. ZOSTAVAX contains potassium This medicine contains less
than 1 mmol potassium (39 milligrams) per dose, that is to say
essentially potassium-free .</p>
 </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take zostavax"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take zostavax"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>ZOSTAVAX should be injected under the skin or into the muscle,
preferably in the upper arm.</p>
<p>If you have a blood clotting disorder or low levels of platelets in
your blood, the injection will be given under the skin. ZOSTAVAX is
given as a single dose. Reconstitution instructions intended for
healthcare professionals are included at the end of the leaflet.</p>
 </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all vaccines and medicines, this vaccine can cause side effects,
although not everybody gets them. Rarely (may affect up to 1 in 1,000
people), allergic reactions may occur. Some of these reactions may be
serious and may include difficulty in breathing or swallowing. If you
have an allergic reaction, call your doctor right away. The following
side effects have been observed:</p>
<p>Very common (may affect more than 1 in 10 people): Redness, pain,
swelling and itching at the injection site*</p>
<p>Common (may affect up to 1 in 10 people): Warmth, bruising, hard
lump, and rash at the injection site*; headache*; pain in the arm or
leg*; joint pain, muscle pain; fever; rash</p>
<p>Uncommon (may affect up to 1 in 100 people): Nausea; swollen gland
(neck, armpit)</p>
<p>Rare (may affect up to 1 in 1,000 people): Hives at the injection
site</p>
<p>Very rare (may affect up to 1 in 10,000 people): Varicella (chicken
pox); shingles; damage of retina caused by inflammation resulting in
changes in sight (in patients under immunosuppressive therapy). *These
adverse reactions have been observed in clinical trials and through
post-marketing surveillance; most of those observed in clinical trials
were reported as mild in intensity. Reporting of side effects If you get
any side effects, talk to your doctor or pharmacist. This includes any
possible side effects not listed in this leaflet. You can also report
side effects directly via the national reporting system listed in
Appendix V. By reporting side effects you can help provide more
information on the safety of this vaccine.</p>
 </div>"""      
        
* section[=].section[+]
  * title = "5. How to store zostavax"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store zostavax"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this vaccine out of the sight and reach of children. Do not use
this vaccine after the expiry date which is stated on the outer carton
after EXP. The expiry date refers to the last day of that month. Store
and transport refrigerated (2 C 8 C). Do not freeze. Keep the vial in
the outer carton in order to protect from light. Do not throw away any
medicines via wastewater or household waste. Ask your pharmacist how to
throw away medicines you no longer use. These measures will help protect
the environment.</p>
 </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What ZOSTAVAX contains After reconstitution, one dose (0.65 mL)
contains: The active substance is: Varicella-zoster virus1, Oka/Merck
strain, (live, attenuated) not less than 19,400 PFU (plaque-forming
units). 1 Produced in human diploid (MRC-5) cells The other ingredients
are: Powder Sucrose, hydrolysed gelatin, sodium chloride (NaCl),
potassium dihydrogen phosphate, potassium chloride (KCl), monosodium
L-glutamate monohydrate, disodium phosphate, sodium hydroxide (NaOH) (to
adjust pH) and urea. Solvent Water for injections What ZOSTAVAX looks
like and contents of the pack The vaccine is a powder for suspension for
injection contained in a single-dose vial, which should be reconstituted
with the solvent provided with the vial of powder. The powder is a white
to off-white compact crystalline plug. The solvent is a clear and
colourless liquid. ZOSTAVAX is available in packs of 1 or 10. Not all
pack sizes may be marketed. Marketing Authorisation Holder and
Manufacturer Marketing Authorisation Holder: Merck Sharp &amp; Dohme
B.V., Waarderweg 39, 2031 BN Haarlem, The Netherlands Manufacturer:
Merck Sharp and Dohme B.V., Waarderweg 39, 2031 BN Haarlem, The
Netherlands For any information about this medicinal product, please
contact the local representative of the Marketing Authorisation Holder.
Belgi /Belgique/Belgien MSD Belgium T l/Tel: +32(0)<a
href="mailto:27766dpoc_belux@merck.com">27766dpoc_belux@merck.com</a>
Lietuva UAB Merck Sharp &amp; Dohme Tel.: <a
href="mailto:+370.5.2780.msd_lietuva@merck.com">+370.5.2780.msd_lietuva@merck.com</a></p>
<pre><code>       , </code></pre>
<p>.: + 359 2 819 <a
href="mailto:3info-msdbg@merck.com">3info-msdbg@merck.com</a>
Luxembourg/Luxemburg MSD Belgium T l/Tel: +32(0)<a
href="mailto:27766dpoc_belux@merck.com">27766dpoc_belux@merck.com</a>
esk republika Merck Sharp &amp; Dohme s.r.o. Tel.: +420 233 010 <a
href="mailto:dpoc_czechslovak@merck.com">dpoc_czechslovak@merck.com</a>
Magyarorsz g MSD Pharma Hungary Kft. Tel.: + <a
href="mailto:36.1.888.5hungary_msd@merck.com">36.1.888.5hungary_msd@merck.com</a>
Danmark MSD Danmark ApS Tlf: + 45 4482 <a
href="mailto:4dkmail@merck.com">4dkmail@merck.com</a> Malta Merck Sharp
&amp; Dohme Cyprus Limited. Tel: 8007 4433 (+356 99917558) <a
href="mailto:malta_info@merck.com">malta_info@merck.com</a></p>
<p>Deutschland MSD Sharp &amp; Dohme GmbH Tel: 0800 673 673 673 (+49 (0)
89 4561 0) <a href="mailto:e-mail@msd.de">e-mail@msd.de</a> Nederland
Merck Sharp &amp; Dohme B.V. Tel: 0800 9999(+31 23 5153153) <a
href="mailto:medicalinfo.nl@merck.com">medicalinfo.nl@merck.com</a>
Eesti Merck Sharp &amp; Dohme O , Tel: <a
href="mailto:+372.614.4msdeesti@merck.com">+372.614.4msdeesti@merck.com</a>
Norge MSD (Norge) AS Tlf: +47 32 20 73 <a
href="mailto:msdnorge@msd.no">msdnorge@msd.no</a></p>
<p>MSD . . . . . : +30 210 98 97 <a
href="mailto:dpoc_greece@merck.com">dpoc_greece@merck.com</a> sterreich
Merck Sharp &amp; Dohme Ges.m.b.H. Tel: +43 (0) 1 26 <a
href="mailto:dpoc_austria@merck.com">dpoc_austria@merck.com</a> Espa a
Merck Sharp &amp; Dohme de Espa a, S.A. Tel: +34 91 321 06 <a
href="mailto:msd_info@merck.com">msd_info@merck.com</a> Polska MSD
Polska Sp. z o.o. Tel.: <a
href="mailto:+48.22.549.51.msdpolska@merck.com">+48.22.549.51.msdpolska@merck.com</a>
France MSD France T l: +33 (0)1 80 46 40 Portugal Merck Sharp &amp;
Dohme, Lda Tel: +351 21 <a
href="mailto:4465inform_pt@merck.com">4465inform_pt@merck.com</a>
Hrvatska Merck Sharp &amp; Dohme d.o.o. Tel: +385 1 66 11 <a
href="mailto:croatia_info@merck.com">croatia_info@merck.com</a> Rom nia
Merck Sharp &amp; Dohme Romania S.R.L Tel: + 4021 529 29 <a
href="mailto:msdromania@merck.com">msdromania@merck.com</a> Ireland
Merck Sharp &amp; Dohme Ireland (Human Health) Limited Tel: +353 (0)1 <a
href="mailto:2998medinfo_ireland@merck.com">2998medinfo_ireland@merck.com</a>
Slovenija Merck Sharp &amp; Dohme, inovativna zdravila d.o.o. Tel: <a
href="mailto:+386.1.520.4msd.slovenia@merck.com">+386.1.520.4msd.slovenia@merck.com</a>
sland Vistor hf. S mi: + 354 535 7Slovensk republika Merck Sharp &amp;
Dohme, s. r.* Tel: +421 2 <a
href="mailto:58282dpoc_czechslovak@merck.com">58282dpoc_czechslovak@merck.com</a>
Italia MSD Italia S.r.l. Tel: 800 23 99 89 (+39 06 361911) <a
href="mailto:medicalinformation.it@msd.com">medicalinformation.it@msd.com</a>
Suomi/Finland MSD Finland Oy Puh/Tel: +358 (0)9 804 <a
href="mailto:info@msd.fi">info@msd.fi</a></p>
<p>Merck Sharp &amp; Dohme Cyprus Limited : 800 00 673 (+357 22866700)
<a href="mailto:cyprus_info@merck.com">cyprus_info@merck.com</a> Sverige
Merck Sharp &amp; Dohme (Sweden) AB Tel: +46 77 <a
href="mailto:5700medicinskinfo@merck.com">5700medicinskinfo@merck.com</a>
Latvija SIA Merck Sharp &amp; Dohme Latvija Tel: <a
href="mailto:+371.67364.msd_lv@merck.com">+371.67364.msd_lv@merck.com</a>
United Kingdom (Northern Ireland) Merck Sharp &amp; Dohme (Human Health)
Limited Tel: +353 (0)1 <a
href="mailto:2998medinfoNI@msd.com">2998medinfoNI@msd.com</a></p>
<p>This leaflet was last revised in &lt;{MM/YYYY}&gt;&lt;{month
YYYY}&gt;. Other sources of information Detailed information on this
medicine is available on the European Medicines Agency website: <a
href="http://www.ema.europa.eu">http://www.ema.europa.eu</a>. The
following information is intended for healthcare professionals only:
Before mixing with the solvent, the powder vaccine is a white to
off-white compact crystalline plug. The solvent is a clear colourless
liquid. When reconstituted, ZOSTAVAX is a semi-hazy to translucent,
off-white to pale yellow liquid. Avoid contact with disinfectants as
they may inactivate the vaccine virus. To reconstitute the vaccine, use
the solvent provided. It is important to use a separate sterile syringe
and needle for each patient to prevent transmission of infectious agents
from one individual to another. One needle should be used for
reconstitution and a separate, new needle for injection. Reconstitution
instructions Withdraw the entire content of the solvent vial into a
syringe. Inject the entire content of the syringe into the vial
containing the powder. Gently agitate to dissolve completely. The
reconstituted vaccine should be inspected visually for any foreign
particulate matter and/or abnormal physical appearance prior to
administration. In the event of either being observed, discard the
vaccine. It is recommended that the vaccine be administered immediately
after reconstitution to minimise loss of potency. Discard if
reconstituted vaccine is not used within 30 minutes. Do not freeze the
reconstituted vaccine. Withdraw the entire content of the reconstituted
vaccine from the vial into a syringe, change the needle and inject the
entire volume by subcutaneous or intramuscular route. Any unused product
or waste material should be disposed of in accordance with local
requirements. See also section</p>
 </div>"""      



Instance: composition-da-e635923c4f0c1291555b7edc27db8608
InstanceOf: CompositionUvEpi
Title: "Composition for zostavax Package Leaflet"
Description:  "Composition for zostavax Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/06/341/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpe635923c4f0c1291555b7edc27db8608)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - zostavax"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. INDLÆGSSEDDEL"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. INDLÆGSSEDDEL"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Indlægsseddel: Information til brugeren"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Indlægsseddel: Information til brugeren"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  
  </div>"""   



* section[=].section[+]
  * title = "Oversigt over indlægssedlen"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Oversigt over indlægssedlen"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen</p>
<ol type="1">
<li>Virkning og anvendelse</li>
<li>Det skal du vide, før du får ZOSTAVAX</li>
<li>Sådan får du ZOSTAVAX</li>
<li>Bivirkninger</li>
<li>Opbevaring</li>
<li>Pakningsstørrelser og yderligere oplysninger</li>
</ol>
 </div>"""   
          

* section[=].section[+]
  * title =  "1. Virkning og anvendelse"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. Virkning og anvendelse"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>ZOSTAVAX er en vaccine, der anvendes til at forebygge helvedesild
(herpes zoster) og herpes zoster- relateret postherpetisk neuralgi
(PHN), dvs. de langvarige nervesmerter, der følger efter helvedesild.
ZOSTAVAX anvendes til vaccination af personer i alderen 50 år og
derover. ZOSTAVAX kan ikke anvendes til behandling af helvedesild i
udbrud eller smerter forbundet med helvedesild i udbrud. Oplysninger om
helvedesild: Hvad er helvedesild? Helvedesild er et smertefuldt,
blæredannende udslæt. Det er normalt begrænset til et bestemt område på
kroppen, og det kan vare adskillige uger. Helvedesild kan medføre svære
og langvarige smerter samt ardannelser. Mindre hyppigt kan der forekomme
bakterielle hudinfektioner, slaphed, muskellammelse og tab af hørelse
eller syn. Helvedesild skyldes den samme virus, som forårsager
skoldkopper. Når man har haft skoldkopper, bliver den virus, som var
skyld i sygdommen, i kroppen i nervecellerne. Undertiden bliver virussen
aktiv igen efter mange år og forårsager helvedesild. Hvad er PHN? Efter
at blærerne i forbindelse med helvedesild er helet op, kan smerterne
blive ved i månedsvis eller årevis, og de kan være svære. Disse
langvarige nervesmerter kaldes postherpetisk neuralgi eller PHN.</p>
<p>40</p>
 </div>"""   
          

             
* section[=].section[+]
  * title = "2. Det skal du vide, før du begynder at tage  zostavax"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. Det skal du vide, før du begynder at tage  zostavax"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Du må ikke få ZOSTAVAX  hvis du er allergisk over for det aktive
stof eller et af de øvrige indholdsstoffer i denne vaccine (herunder
neomycin (som kan forekomme som reststof) eller et eller flere af
indholdsstofferne, der er angivet under punkt 6)  hvis du har en
blodsygdom eller enhver form for kræft, der svækker immunsystemet  hvis
lægen har fortalt dig, at du har et svækket immunsystem som følge af
sygdom, lægemidler eller anden behandling  hvis du har aktiv
tuberkulose, der ikke behandles  hvis du er gravid (graviditet skal
endvidere undgås 1 måned efter vaccination, se Graviditet og amning).
Advarsler og forsigtighedsregler Kontakt lægen eller apotekspersonalet,
før du får ZOSTAVAX, hvis du har oplevet et eller flere af følgende: 
hvis du har eller har haft sygdomsrelaterede problemer eller allergiske
reaktioner  hvis du har feber  hvis du har hiv-infektion Fortæl det
til lægen, inden du får denne vaccine, hvis du på noget tidspunkt har
haft en allergisk reaktion på indholdsstofferne i vaccinen (herunder
neomycin (som kan forekomme som reststof) eller et eller flere af
indholdsstofferne, der er angivet under punkt 6). Som med mange vacciner
beskytter ZOSTAVAX muligvis ikke fuldstændigt alle personer, der
vaccineres. Hvis du har en sygdom, der vedrører blodets evne til at
størkne, eller hvis du har for få blodplader i blodet, skal
indsprøjtningen gives under huden, da det kan begynde at bløde, hvis den
bliver givet i en muskel. Brug af anden medicin sammen med ZOSTAVAX
Fortæl altid lægen eller apotekspersonalet, hvis du bruger anden medicin
(eller vacciner), for nylig har brugt anden medicin (eller vacciner)
eller planlægger at bruge anden medicin (eller vacciner). ZOSTAVAX kan
gives samtidig med inaktiveret influenzavaccine. De to vacciner skal
gives som separate injektioner forskellige steder på kroppen. Kontakt
lægen eller sygeplejersken for information om samtidig administration af
ZOSTAVAX og pneumokokpolysaccharidvaccinen. Graviditet og amning
ZOSTAVAX må ikke gives til gravide. Kvinder i den fødedygtige alder skal
tage nødvendige forholdsregler for at undgå graviditet i 1 måned efter
vaccination. Rådfør dig med lægen, hvis du ammer eller planlægger at
amme. Lægen vil afgøre, om du kan vaccineres med ZOSTAVAX. Hvis du er
gravid eller ammer, har mistanke om, at du er gravid, eller planlægger
at blive gravid, skal du spørge din læge eller apotekspersonalet til
råds, før du bliver vaccineret. Trafik- og arbejdssikkerhed Der
foreligger ingen oplysninger, som antyder, at ZOSTAVAX påvirker evnen
til at køre bil og betjene maskiner.</p>
<p>41 ZOSTAVAX indeholder natrium Dette lægemiddel indeholder mindre end
1 mmol (23 milligram) natrium pr. dosis, dvs. det er i det væsentlige
natriumfrit. ZOSTAVAX indeholder kalium Dette lægemiddel indeholder
mindre end 1 mmol (39 milligram) kalium pr. dosis, dvs. det er i det
væsentlige kaliumfrit.</p>
 </div>"""   
                    
* section[=].section[+]
  * title =  "3. Sådan skal du tage zostavax"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. Sådan skal du tage zostavax"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>ZOSTAVAX skal injiceres under huden eller i en muskel, helst på
overarmen. Hvis du har en sygdom, der vedrører blodets evne til at
størkne, eller hvis du har for få blodplader i blodet, bliver
indsprøjtningen givet under huden. ZOSTAVAX gives i en enkelt dosis.
Rekonstitutionsanvisninger til læger og sundhedspersonale findes sidst i
indlægssedlen.</p>
 </div>"""         

        
* section[=].section[+]
  * title = "4. Bivirkninger"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Bivirkninger"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Denne vaccine kan som alle andre vacciner og lægemidler give
bivirkninger, men ikke alle får bivirkninger. I sjældne tilfælde (kan
forekomme hos op til 1 ud af 1.000 personer) kan der forekomme
allergiske reaktioner. Nogle af disse reaktioner kan være alvorlige og
omfatte åndedrætsbesvær eller synkebesvær. Hvis du får en allergisk
reaktion, skal du omgående søge læge. Der er set følgende bivirkninger:
 Meget almindelige (kan forekomme hos flere end 1 ud af 10 personer):
rødme, smerter, hævelse og kløe på injektionsstedet.*  Almindelige (kan
forekomme hos op til 1 ud af 10 personer): varmefornemmelse, blå mærker,
en hård knude og udslæt på injektionsstedet*, hovedpine*, smerter i arme
eller ben*, ledsmerter, muskelsmerter, feber, udslæt.  Ikke almindelige
(kan forekomme hos op til 1 ud af 100 personer): kvalme, hævede
lymfeknuder (halsen, armhulen).  Sjældne (kan forekomme hos op til 1 ud
af 1.000 personer): nældefeber på injektionsstedet.  Meget sjældne (kan
forekomme hos op til 1 ud af 10.000 personer): skoldkopper (varicella),
helvedesild og beskadigelse af retina forårsaget af inflammation med
efterfølgende synsmæssige forandringer (hos patienter, som modtager
immunsuppressiv terapi).</p>
<p>*Disse bivirkninger er set i videnskabelige forsøg og ved opfølgning
efter markedsføring. De fleste af de bivirkninger, der blev set i de
videnskabelige forsøg, blev rapporteret som værende af mild
sværhedsgrad. Indberetning af bivirkninger Hvis du oplever bivirkninger,
bør du tale med din læge, apotekspersonalet eller sygeplejersken. Dette
gælder også mulige bivirkninger, som ikke er medtaget i denne
indlægsseddel. Du eller dine pårørende kan også indberette bivirkninger
direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe
med at fremskaffe mere information om sikkerheden af dette
lægemiddel.</p>
<p>42</p>
 </div>"""      
        
* section[=].section[+]
  * title = "5. Opbevaring"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. Opbevaring"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar denne vaccine utilgængeligt for børn. Brug ikke denne vaccine
efter den udløbsdato, der står på den ydre karton efter EXP.
Udløbsdatoen er den sidste dag i den nævnte måned. Opbevares i køleskab
og transporteres nedkølet (2 °C-8 °C). Må ikke nedfryses. Opbevar
hætteglasset i den ydre karton for at beskytte mod lys. Spørg
apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn
til miljøet må du ikke smide medicinrester i afløbet, toilettet eller
skraldespanden.</p>
 </div>"""      
        
        
* section[=].section[+]
  * title = "6. Pakningsstørrelser og yderligere oplysninger"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Pakningsstørrelser og yderligere oplysninger"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>ZOSTAVAX indeholder: Efter rekonstitution indeholder en dosis (0,65
ml): Aktivt stof: Varicella-zoster-virus1, Oka/Merck-stamme, (levende,
svækket) ikke under 19.400 PFU (plaquedannende enheder). 1 Produceret i
humane diploide (MRC-5) celler. Øvrige indholdsstoffer: Pulver
Saccharose, hydrolyseret gelatine, natriumchlorid (NaCl),
kaliumdihydrogenphosphat, kaliumchlorid (KCl),
mononatrium-L-glutamatmonohydrat, dinatriumphosphat, natriumhydroxid
(NaOH) (til justering af pH) og urinstof. Solvens Vand til
injektionsvæsker Udseende og pakningsstørrelser Vaccinen er et pulver,
der skal opløses før injektion, opbevaret i et hætteglas, som indeholder
en enkelt dosis. Indholdet rekonstitueres med solvens, der følger med
pulveret. Pulveret er en hvid til råhvid kompakt krystallinsk masse.
Solvensen er en klar og farveløs væske. ZOSTAVAX fås i pakninger med 1
eller 10 stk. Ikke alle pakningsstørrelser er nødvendigvis markedsført.
Indehaver af markedsføringstilladelsen og fremstiller Indehaver af
markedsføringstilladelsen: Merck Sharp &amp; Dohme B.V., Waarderweg 39,
2031 BN Haarlem, Holland Fremstiller: Merck Sharp and Dohme B.V.,
Waarderweg 39, 2031 BN Haarlem, Holland 43 Hvis du ønsker yderligere
oplysninger om dette lægemiddel, skal du henvende dig til den lokale
repræsentant for indehaveren af markedsføringstilladelsen:
België/Belgique/Belgien MSD Belgium Tél/Tel: +32(0)27766211 <a
href="mailto:dpoc_belux@merck.com">dpoc_belux@merck.com</a> Lietuva UAB
Merck Sharp &amp; Dohme Tel.: +370.5.2780.247 <a
href="mailto:msd_lietuva@merck.com">msd_lietuva@merck.com</a> България
Мерк Шарп и Доум България ЕООД, тел.: + 359 2 819 3737 <a
href="mailto:info-msdbg@merck.com">info-msdbg@merck.com</a>
Luxembourg/Luxemburg MSD Belgium Tél/Tel: +32(0)27766211 <a
href="mailto:dpoc_belux@merck.com">dpoc_belux@merck.com</a> Česká
republika Merck Sharp &amp; Dohme s.r.o. Tel.: +420 233 010 111 <a
href="mailto:dpoc_czechslovak@merck.com">dpoc_czechslovak@merck.com</a>
Magyarország MSD Pharma Hungary Kft. Tel.: + 36.1.888.5300 <a
href="mailto:hungary_msd@merck.com">hungary_msd@merck.com</a> Danmark
MSD Danmark ApS Tlf: + 45 4482 4000 <a
href="mailto:dkmail@merck.com">dkmail@merck.com</a> Malta Merck Sharp
&amp; Dohme Cyprus Limited. Tel: 8007 4433 (+356 99917558) <a
href="mailto:malta_info@merck.com">malta_info@merck.com</a> Deutschland
MSD Sharp &amp; Dohme GmbH Tel: 0800 673 673 673 (+49 (0) 89 4561 0) <a
href="mailto:e-mail@msd.de">e-mail@msd.de</a> Nederland Merck Sharp
&amp; Dohme B.V. Tel: 0800 9999000 (+31 23 5153153) <a
href="mailto:medicalinfo.nl@merck.com">medicalinfo.nl@merck.com</a>
Eesti Merck Sharp &amp; Dohme OÜ, Tel: +372.614.4200 <a
href="mailto:msdeesti@merck.com">msdeesti@merck.com</a> Norge MSD
(Norge) AS Tlf: +47 32 20 73 00 <a
href="mailto:msdnorge@msd.no">msdnorge@msd.no</a> Ελλάδα MSD Α.Φ.Β.Ε.Ε.
Τηλ: +30 210 98 97 300 <a
href="mailto:dpoc_greece@merck.com">dpoc_greece@merck.com</a> Österreich
Merck Sharp &amp; Dohme Ges.m.b.H. Tel: +43 (0) 1 26 044 <a
href="mailto:dpoc_austria@merck.com">dpoc_austria@merck.com</a> España
Merck Sharp &amp; Dohme de España, S.A. Tel: +34 91 321 06 00 <a
href="mailto:msd_info@merck.com">msd_info@merck.com</a> Polska MSD
Polska Sp. z o.o. Tel.: +48.22.549.51.00 <a
href="mailto:msdpolska@merck.com">msdpolska@merck.com</a> France MSD
France Tél: +33 (0)1 80 46 40 40 Portugal Merck Sharp &amp; Dohme, Lda
Tel: +351 21 4465700 <a
href="mailto:inform_pt@merck.com">inform_pt@merck.com</a> Hrvatska Merck
Sharp &amp; Dohme d.o.o. Tel: +385 1 66 11 333 <a
href="mailto:croatia_info@merck.com">croatia_info@merck.com</a> România
Merck Sharp &amp; Dohme Romania S.R.L Tel: + 4021 529 29 00 <a
href="mailto:msdromania@merck.com">msdromania@merck.com</a></p>
<p>44 Ireland Merck Sharp &amp; Dohme Ireland (Human Health) Limited
Tel: +353 (0)1 2998700 <a
href="mailto:medinfo_ireland@merck.com">medinfo_ireland@merck.com</a>
Slovenija Merck Sharp &amp; Dohme, inovativna zdravila d.o.o. Tel:
+386.1.520.4201 <a
href="mailto:msd.slovenia@merck.com">msd.slovenia@merck.com</a> Ísland
Vistor hf. Sími: + 354 535 7000 Slovenská republika Merck Sharp &amp;
Dohme, s. r.* Tel: +421 2 58282010 <a
href="mailto:dpoc_czechslovak@merck.com">dpoc_czechslovak@merck.com</a>
Italia MSD Italia S.r.l. Tel: 800 23 99 89 (+39 06 361911) <a
href="mailto:medicalinformation.it@msd.com">medicalinformation.it@msd.com</a>
Suomi/Finland MSD Finland Oy Puh/Tel: +358 (0)9 804 650 <a
href="mailto:info@msd.fi">info@msd.fi</a> Κύπρος Merck Sharp &amp; Dohme
Cyprus Limited Τηλ: 800 00 673 (+357 22866700) <a
href="mailto:cyprus_info@merck.com">cyprus_info@merck.com</a> Sverige
Merck Sharp &amp; Dohme (Sweden) AB Tel: +46 77 5700488 <a
href="mailto:medicinskinfo@merck.com">medicinskinfo@merck.com</a>
Latvija SIA Merck Sharp &amp; Dohme Latvija Tel: <a
href="mailto:+371.67364.msd_lv@merck.com">+371.67364.msd_lv@merck.com</a>
United Kingdom (Northern Ireland) Merck Sharp &amp; Dohme (Human Health)
Limited Tel: +353 (0)1 2998700 <a
href="mailto:medinfoNI@msd.com">medinfoNI@msd.com</a> Denne
indlægsseddel blev senest ændret &lt;{MM/ÅÅÅÅ}&gt;&lt;{måned ÅÅÅÅ}&gt;.
Andre informationskilder Du kan finde yderligere oplysninger om dette
lægemiddel på Det Europæiske Lægemiddelagenturs hjemmeside <a
href="http://www.ema.europa.eu/">http://www.ema.europa.eu/</a>.</p>
<p>45 Nedenstående oplysninger er til læger og sundhedspersonale: Før
opblanding med solvensen er vaccinens pulver en hvid til råhvid kompakt
krystallinsk masse. Solvensen er en klar, farveløs væske. Efter
rekonstitution er ZOSTAVAX en let sløret til gennemskinnelig, råhvid til
bleggul væske. Undgå kontakt med desinficerende midler, da disse kan
inaktivere vaccinevirus. Brug den vedlagte solvens til rekonstitution af
vaccinen. Det er vigtigt at anvende en separat steril injektionssprøjte
og kanyle til hver enkelt person for at forebygge transmission af
smitsomme stoffer fra en person til en anden. Der skal anvendes en
kanyle til rekonstitution, og en anden separat kanyle skal anvendes til
injektion. Rekonstitutionsanvisninger Træk hele indholdet i hætteglasset
med solvens op i en injektionssprøjte. Hele sprøjtens indhold injiceres
i hætteglasset med pulver. Omryst forsigtigt for at opløse pulveret
fuldstændigt. Inden administration skal den rekonstituerede vaccine
undersøges visuelt for fremmede partikler og/eller usædvanligt udseende.
Hvis noget af dette forekommer, skal vaccinen kasseres. Det anbefales,
at vaccinen gives straks efter rekonstitution for at minimere tab af
styrke. Den rekonstituerede vaccine skal bortskaffes, hvis den ikke
anvendes inden for 30 minutter. Den rekonstituerede vaccine må ikke
nedfryses. Hele hætteglassets indhold af rekonstitueret vaccine trækkes
op i en injektionssprøjte, kanylen skiftes og hele mængden injiceres
subkutant eller intramuskulært. Ikke anvendt lægemiddel samt affald
heraf skal bortskaffes i henhold til lokale retningslinjer. Se også
punkt</p>
 </div>"""      





                    
Instance: bundlepackageleaflet-en-e635923c4f0c1291555b7edc27db8608
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for zostavax Package Leaflet for language en"
Description: "ePI document Bundle for zostavax Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-e635923c4f0c1291555b7edc27db8608"
* entry[0].resource = composition-en-e635923c4f0c1291555b7edc27db8608

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpe635923c4f0c1291555b7edc27db8608"
* entry[=].resource = mpe635923c4f0c1291555b7edc27db8608
                            
                    
Instance: bundlepackageleaflet-da-e635923c4f0c1291555b7edc27db8608
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for zostavax Package Leaflet for language da"
Description: "ePI document Bundle for zostavax Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-e635923c4f0c1291555b7edc27db8608"
* entry[0].resource = composition-da-e635923c4f0c1291555b7edc27db8608

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpe635923c4f0c1291555b7edc27db8608"
* entry[=].resource = mpe635923c4f0c1291555b7edc27db8608
                            
                    



Instance: mpe635923c4f0c1291555b7edc27db8608
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product ZOSTAVAX powder and solvent for suspension for injection"
Description: "ZOSTAVAX powder and solvent for suspension for injection"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/06/341/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "ZOSTAVAX powder and solvent for suspension for injection"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: e635923c4f0c1291555b7edc27db8608ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "zostavax"

* status = #current
* mode = #working

* title = "List of all ePIs associated with zostavax"

* subject = Reference(mpe635923c4f0c1291555b7edc27db8608)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#zostavax "zostavax"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-e635923c4f0c1291555b7edc27db8608) // zostavax en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-e635923c4f0c1291555b7edc27db8608) // zostavax da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-e635923c4f0c1291555b7edc27db8608
InstanceOf: List
Description: "ePI document List for zostavax Package Leaflets"

* insert e635923c4f0c1291555b7edc27db8608ListRuleset
    